Literature DB >> 32003207

The optimal core number and site for MRI-targeted biopsy of prostate? A systematic review and pooled analysis.

Xiang Tu1, Tianhai Lin1, Diming Cai2, Zhenhua Liu1, Lu Yang1, Qiang Wei3.   

Abstract

INTRODUCTION: Prebiopsy multiparametric magnetic resonance imaging (mpMRI) has been increasingly utilized for patients of suspicious prostate cancer (PCa). However, the optimal core number and site for MRI-targeted biopsy have not been clearly elucidated. EVIDENCE ACQUISITION: A systematic search in Pubmed, Embase and Ovid up to June 2019 was conducted and we identified studies reporting detection details of every MRI-targeted core. The incremental diagnostic value of performing additional cores was pooled on per-lesion analysis. Our secondary outcome concentrated on detection accuracy for cores of different site within one lesion. EVIDENCE SYNTHESIS: Five studies comprising 2291 patients were identified to elucidate the association between targeted core number and cancer detection rates. Adding the second core to the first one resulted in 19.8% (range: 13.6-26.7%) increase in the detection rate of clinically significant lesions, and adding the third one to the first two resulted in 11.5% (range: 7.8-14.3%) increase. The incremental value of adding the fourth or the fifth core was 6.0% (4.7%, 6.9%) and 4.1% respectively. Four studies arranging MRI-targeted biopsy of more than two cores in well-determined sequences indicated more positive cores with higher cancer grade through center of the lesions.
CONCLUSIONS: Increasing the number of samples per target from one to two, or two to three resulted in a nonnegligible incremental detection rate of clinically significant lesions, while obtaining more than 3 cores per target provided a diminished incremental value. And performing targeted cores accurately through center of the lesions may help improve diagnostic accuracy.

Entities:  

Year:  2020        PMID: 32003207     DOI: 10.23736/S0393-2249.20.03639-5

Source DB:  PubMed          Journal:  Minerva Urol Nefrol        ISSN: 0393-2249            Impact factor:   3.720


  2 in total

1.  TRUS-Guided Target Biopsy for a PI-RADS 3-5 Index Lesion to Reduce Gleason Score Underestimation: A Propensity Score Matching Analysis.

Authors:  Jae Hoon Chung; Byung Kwan Park; Wan Song; Minyong Kang; Hyun Hwan Sung; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee
Journal:  Front Oncol       Date:  2022-01-24       Impact factor: 6.244

2.  Establishment of an Individualized Predictive Model to Reduce the Core Number for Systematic Prostate Biopsy: A Dual Center Study Based on Stratification of the Disease Risk Score.

Authors:  Zeyu Chen; Min Qu; Xianqi Shen; Shaoqin Jiang; Wenhui Zhang; Jin Ji; Yan Wang; Jili Zhang; Zhenlin Chen; Lu Lin; Mengqiang Li; Cheng Wu; Xu Gao
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.